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ABSTRACT
Introduction: Advanced ovarian cancer is often
a fatal disease as chemotherapeutic drugs have
limited effectiveness. Better targeted therapy is
needed to improve the survival and quality of
life for these women. Receptor tyrosine kinases
including EGFR, Her-2 and c-Met are associated
with a poor prognosis in ovarian cancer.
Therefore, the co-activation of these receptors
may be crucial for growth promoting activity.
In this study, we explored the effect of
combining two small molecule inhibitors that
target the EGFR/Her-2 and c-Met receptor
tyrosine kinases in two ovarian cancer cell
lines. The aim of this study was to investigate
the combined inhibition activity of a dual
EGFR/Her-2 inhibitor (canertinib) and a c-Met
inhibitor (PHA665752) in ovarian cancer cell
lines in 3D cell aggregates.
Methods: OVCAR-5 and SKOV-3 ovarian cancer
cell lines were cultured on a non-adherent
surface to produce 3D cell clusters and
aggregates. Cells were exposed to canertinib
and PHA665752, both individually and in
combination, for 48 h. The effect on growth,
metabolism and the expression/
phosphorylation of selective signaling proteins
associated with EGFR, Her-2 and c-Met were
investigated.
Results: The single drug treatments
significantly decreased cell growth and altered
the expression of signaling proteins in
OVCAR-5 and SKOV-3 cell lines. The
combination treatment showed greater
reduction of cell numbers for both cell lines.
Total expression and phosphorylation of
signaling proteins were further reduced in the
combination drug treatments, compared to the
single inhibitor treatments.
Conclusion: Our findings suggest that the
concurrent targeting of more than one
receptor tyrosine kinase may be useful in
developing more effective targeted drug
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regimens for patients, who have EGFR, Her-2
and c-Met positive ovarian cancer cells.
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INTRODUCTION
Ovarian cancer is the leading cause of death from
gynecological cancers in developed countries.
The majority of ovarian cancer patients are
diagnosed with an advanced stage of the
disease, and as such they typically have a 5-year
survival rate lower than 30% [1]. For themajority
of women, cytotoxic chemotherapeutics have
limited efficacy. Therefore, there is an urgent
need for alternative anticancer agents that have
the potential to control tumor growth, improve
the quality of life, and increase the longevity of
patients.
A number of targeted anticancer drugs have
been studied; among these drugs are small
molecule inhibitors of receptor tyrosine
kinases. A subset of cancer cells is dependent
on the over activation of epidermal growth
factor receptor proteins including EGFR and
Her-2. Therefore, an inhibitor that specifically
blocks these receptors may have clinical
activity. Specific inhibitors of EGFR and Her-2
including gefitinib, erlotinib, lapatinib, and a
monoclonal antibody Herceptin have been
approved by the FDA to treat different types of
cancers that include breast cancer, colon cancer
and non-small cell lung cancer, NSCLC [2, 3].
The EGFR and Her-2 inhibitors as a
monotherapy show minimal clinical benefit in
ovarian cancer trails [4, 5]. The lack of clinical
efficacy of these inhibitors is perhaps due to
activation of multiple receptor tyrosine kinases
and the activation of several down stream
signaling proteins. In this study, we explore
the possibility that targeting of multiple
receptor tyrosine kinases will lead to greater
effects on tumor growth potential.
Some advanced ovarian cancer cells have
been shown to possess high levels of the
receptors EGFR and Her-2 [6]. It is the
activation of these receptors that may promote
the growth of malignant cells, and the over
expression of these receptors has been
associated with a poor prognosis and invasive
phenotypic changes [7, 8]. There is evidence to
suggest that EGFR/Her-2 expressing malignant
cells may not be sensitive to the EGFFR and
Her-2 inhibitors as ovarian cancer cells are able
to use alternate a receptor tyrosine kinase for
growth promotion [9]. The c-Met is also a
receptor tyrosine kinase, which has elevated
levels in ovarian cancer cells [10]. The c-Met
receptors are activated when they are bound by
the hepatocyte growth factor, HGF, which is
elevated in the ascitic fluid of women with
advanced stages of ovarian cancer [11]. The
EGFR, Her-2 and c-Met receptors share common
downstream signaling molecules that can
promote cell survival, motility, and invasion
and cross-communication between these three
receptors may promote cancer progression and
resistance to therapy [12]. Thus, c-Met could be
an additional potential target for cancer
treatment and raises the strategic possibility of
combined targets of receptor tyrosine kinases
concurrently.
Candidate molecules for such combined
strategies are canertinib and PHA665752.
Canertinib, also known as CI-1033, is an
irreversible inhibitor of receptor tyrosine
kinases, binding to the ATP-binding site. It has
shown potent effects against several cancer cell
lines targeting EGFR and Her-2. Clinical trials of
canertinib have been conducted against a
number of tumor types, including breast
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cancer [13], NSCLC [3], and advanced ovarian
cancer [5]. However, canertinib alone showed
modest activities in clinical studies with ovarian
cancer patients [5]. PHA665752 is a reversible
inhibitor of c-Met, which at nano-molar
concentrations has shown in vivo anti-tumor
activity [14].
Advanced ovarian cancer patients often have
ascitic fluid in the abdominal cavity. In the
fluid, ovarian malignant cells form 3D
structures; these microscopic clusters and
aggregates are a major source of secondary
growth potential [15, 16]. These clusters and
aggregates then deposit on the peritoneal lining
and the surface of internal organs to continue
their growth. Therefore, it is appropriate to use
cell clusters and aggregates as an in vitro cell
model to replicate the behavior of ovarian
cancer cells. We hypothesized that floating cell
clusters and aggregates ovarian cancer cells may
use the concurrent activation of EGFR, Her-2
and c-Met to sustain growth and cell survival.
Combined inhibition of these receptors will
produce a greater anti-growth effect in ovarian
cancer cells. The aim of the present study was to
test the effect of such combined inhibitors on
3D cell cultures of two ovarian cancer cell lines,
OVCAR-5- and SKOV-3.
METHODS
The human ovarian adenocarcinoma cell lines,
OVCAR-5 and SKOV-3 were used. Both cell lines
were obtained from Dr. Judith Mckenzie,
Haematology Research group, University of
Otago, Christchurch, New Zealand. OVCAR-5
and SKOV-3 cells were maintained in DMEM/
F12 or MEMmedia (GIBCO, Life Technologies,
New Zealand), respectively, both supplemented
with 5% fetal bovine serum (FBS) (GIBCO, Life
Technologies, New Zealand), PenStrep
(GIBCO, Life Technologies, New Zealand) at a
working concentration of 100 units/ml
penicillin, 100 lg/ml streptomycin, 2 mM
glutaMAXTM (GIBCO, Life Technologies, New
Zealand), and 2 lg/ml Fungizone (Life
Technologies, New Zealand). The final
concentration of glucose in the media was
5.5 mM. The respective supplemented media is
henceforth referred to as working media. Cells
were maintained at 37 C in a humidified 5%
CO2 atmosphere. This article does not contain
any studies with human or animal subjects
performed by any of the authors.
Generation of 3D Cell Aggregates
Twelve or twenty-four welled culture plates
were coated with 24 mg/ml poly
(2-hydroxyethylmethacrylate) (poly-HEMA)
(Sigma, New Zealand), a polymer that
prevents cells from adhering to the surface of
culture wells. The poly-HEMA was dissolved in
95% ethanol and heated to approximately
70 C until completely dissolved. The cell
culture plates were coated with 300 lL
poly-HEMA solution and placed overnight on
an orbital shaker at 37 C and then left to cool
down prior the cell culture. Plates were
washed with PBS pH 7.4. Cell monolayers
were incubated with diluted 19 Trypsin–EDTA
(Thermo Fisher Scientific, New Zealand) for
20–30 min to detach cells from the flask. Cell
numbers were determined with a
hemocytometer to ensure that each well
contained approximately 100,000 cells with a
total volume of 1 ml working media. Cells
were then incubated at 37 C in a humidified
5% CO2 atmosphere for 6 days to obtain
cellular aggregates. Media were removed and
replaced with 1 ml of fresh media every
second day.
Oncol Ther (2016) 4:257–274 259
Treatments with Canertinib
and PHA665752, HGF and EGF
Canertinib (CI-1033) was purchased from LC
laboratories (Massachusetts, USA) and
PHA665752 was obtained from Sigma
(Auckland, New Zealand). Both compounds
were dissolved in 100% DMSO. Final DMSO
volumes were normalized for all experiments
and were less than 0.5% (v/v). Cells were then
synchronized in media without FBS for 24 h,
before they were exposed to the inhibitors and
growth factors. Cells were activated with HGF
and EGF (GIBCO, Life Technologies, New
Zealand) during drug treatment. Fresh working
media containing combined growth factors at
concentrations of 0.2 and 20 ng/ml were used to
activate cellular activity. In our dose-dependent
stimulation of a single inhibitor, we used a
range of (2–4 lM) canertinib and (0.5–2.0 lM)
PHA665752.
For the combined treatments, cells were
treated with both canertinib (3 lM) and
PHA665752 (1 lM for 24 h. After the first 24 h,
PHA665752 was re-added to the
combination-treated cells, and cells were
incubated for a further 24 h before harvesting.
At least three independent experiments were
carried out and each individual experiment was
carried out in triplicates.
Analysis of Morphology and Cell Viability
of Cells in Clusters and Aggregates
After culturing for 6 days, cell aggregates of
both cell lines were imaged using an inverted
light microscope equipped with a digital
camera, using a 109/0.25 N.A. objective lens
(ACCU-SCOPE 3032). After treatment periods,
cells in clusters and aggregates were harvested
and digested with 1 9 trypsin–EDTA to obtain
single cell suspensions, and cells were counted
using a hemocytometer to assess cell viability.
Immunofluorescent Detection
of Receptors
For immunofluorescent imaging, OVCAR-5 and
SKOV-3 cells were cultured for 6 days to
generate cell clusters and aggregates. The
media were refreshed every second day. Cell
clusters and aggregates were harvested and fixed
with ice-cold 50% (v/v) acetone/methanol
solution. OVCAR-5 cell clusters were washed
twice with ice-cold PBS, pH 7.4 and
re-suspended in 200 ll cold PBS. Clusters were
then mounted on poly-lysine coated
microscope slides and left to dry at 37 C.
Once cells were dry, cells were blocked with
4% BSA in PBS. Cells were stained overnight
with a 1:200 dilution of primary antibody at
4 C. Cells were then washed with ice-cold PBS
pH 7.4. A 1:500 dilution of secondary antibody,
conjugated with FITC was added to cells and
further incubated for 60 min. The secondary
antibody solution was removed and 500 ll of
10 lg/ml DAPI was added to the cells and left
for 20 min in the dark. Cells were then washed
with 0.1% Tween-20 in PBS pH 7.4 and were
mounted in ice-cold anti-fading solution (2 mg/
ml p-phenylenediamine in 80% glycerol, pH
7.8).
SKOV-3 aggregates were washed with PBS pH
7.4 and stained with aniline blue dye for
20 min. Cells were washed with milliQ water
twice before they were embedded in a liquid
OCT, an embedding medium used to aid
sectioning of frozen tissue samples in a
cryostat (Thermo Fisher Scientific, New
Zealand). The liquid OCT blocks were frozen
at -20 C for at least 24 h. Sections (7 lm thick)
from the block of frozen OCT were cut using a
CM186UV Cryostat (Lieca BIOSYSTEM,
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Deutschland). Immunofluorescent staining was
carried out on both cell lines with anti-EGFR
(SC120), anti-Her-2 (SC-7301), and anti-c-Met
(SC10) primary antibodies (Santa Cruz).
Fluorescent images were captured using an
epifluorescence microscope with a 409/
1.3 N.A. oil/DIC objective lens (AxioVision 4.5.
Apotome software, Carl Zeiss, Oberkochen,
Germany).
Immunoblotting Analysis
Cell clusters and aggregates were harvested by
centrifugation at 400g for 5 min, and the cell
pellets were lyzed in cold RIPA buffer (50 mM
Tris–HCl pH 7.4, 100 mM NaCl, 5 mM EDTA,
1% NP-40, 0.1% SDS, 0.5% Na deoxycholate,
1 mM Na2VO3 containing protease inhibitor
cocktail tablets (Complete Mini, Roche, New
Zealand). The cell lysates were left on ice for a
further 30 min. Sample buffer [0.2% (v/v)
bromophenol blue, 25% (v/v) glycerol, 10%
SDS in Tris–HCl, and pH 6.8] was added and
protein lysates were boiled for 10 min. Prior to
loading, the cell lysates were mixed and
centrifuged at 9700g for 5 min. A total of
10 lg protein lysate was loaded and separated
by SDS-PAGE using a 7% stacking gel and a
10% separating gel. The SDS-PAGE was run at
120 V using Tris–glycine running buffer. The
SDS-PAGE markers used were MagicMarkTM XP
Western Standard (Thermo Fisher Scientific,
New Zealand) and Precision Plus Protein
standard (Bio-Rad, Hercules, USA). Separated
proteins were electro-blotted onto a poly-vinyl
membrane (PVDF) (GE Healthcare Life
Sciences, New Zealand). The electro blot was
run at 100 V for 60 min in cold Tris–glycine
running buffer containing 10% v/v methanol.
The membranes were blocked for 60 min with
either 5% (w/v) non-fat skim milk (Pams
brand, New World, New Zealand) or 1% (w/v)
bovine serum albumin (Thermo Fisher
Scientific, New Zealand) made up in TBS-T
buffer or with Pierce Protein-Free Blocking
Buffer (Thermo Scientific, New Zealand).
Antibodies (detailed below) were diluted from
1:500 to 1:1000 with the appropriate blocking
solution. Membranes were incubated with the
primary antibodies overnight at 4 C. The
membranes were washed with TBS-T buffer
on an orbital shaker for 4 9 10 min and then
incubated with secondary antibody on an
orbital shaker for 90 min at room
temperature. Membranes were further washed
four times with TBS-T. Antibody localization
was determined using a chemiluminescent
detection kit (Amersham ECL Prime Western
Blotting Detection Reagent Kit, GE Healthcare).
The protein bands were visualized and a
densitometry analysis was performed using
Alliance 4.7, Unitec (Cambridge, UK). Cell
lysates were collected from at least three
separated cell culture experiments. The
primary antibodies used in this study were
anti-PCNA (sc-25280), anti-GAPDH (sc-25778),
anti-EGFR (sc-03), anti-p-EGFR (sc-101668),
anti-pHER2 (sc-12352-R), anti-ERK (sc-94),
anti-pERK1/2 (sc-7383), Anti-c-Met (sc-10),
anti-p-Met (sc-101736), anti-Akt (sc-8312),
and anti-p-Akt (sc-101629) (all from Santa
Cruz Biotechnology Inc., Santa Cruz, CA,
USA, apart from the anti-Her2 which was
purchased from BD Biosciences (Auckland,
New Zealand)). The two secondary antibodies
used in this study were bovine anti-rabbit
IgG-HRP (sc-2385) and bovine anti-mouse
IgG-HRP (sc-2380).
Statistical Analysis
Statistical analysis of data was carried out using
Prism graph pad. One-way ANOVAs were
carried out where p\0.05 (*), p\0.01 (**),
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p\0.001 (***), and p\0.0001 (****) were
considered to indicate levels of statistical
significance. Prior to analysis percentile and
ratio-metric values were logarithmically
transformed. All data are presented as
mean ± SEM. Each experiment was repeated at
least three times.
RESULTS
Morphology and Expression EGFR, Her-2,
and c-Met
OVCAR-5 cells formed small cell clusters when
cultured on a non-adherent surface (Fig. 1a). In
contrast, SKOV-3 cells formed large cellular
aggregates with dense multicellular structures
(Fig. 1b). To determine the presence of cell
receptors, we immunofluorescently labeled
OVCAR-5 clusters and SKOV-3 cellular
aggregates. OVCAR-5 clusters were EGFR
(Fig. 1c) and c-Met positive (Fig. 1g), but had
low expression of Her-2 (Fig. 1e). SKOV-3
aggregates were EGFR, Her-2 and c-Met
positive (Fig. 1d, f, h).
EGF and HGF Increase the Growth
of OVCAR-5 Clusters and SKOV-3
Aggregates
We chose two concentrations of the growth
factor EGF and HGF; a physiological
concentration (0.2 ng/ml) that approximates
to that present in ovarian cancer patients, and
a concentration that is commonly used in
in vitro studies (20 ng/ml). The growth of
OVCAR-5 cell clusters was not increased in the
presence of the physiological concentration of
growth factor (p = 0.4076). However, the higher
Fig. 1 Morphology of cell clusters and the expression of
EGFR, Her-2 and c-Met. Microscopic images of
OVCAR-5 ovarian cancer cell clusters (a) and SKOV-3
ovarian cancer cell aggregates (b). The expression of
epidermal growth factor receptor (EGFR) in OVCAR-5
(c) and SKOV-3 (d). Total expression of human epidermal
growth factor receptor-2 (Her-2) in OVCAR-5 (e) and
SKOV-3 (f). Total expression of mesenchymal epithelial
transition factor (c-Met) receptors in OVCAR-5 (g) and
SKOV-3 (h)
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concentration significantly increased growth
(p[0.0001) (Fig. 2a). Both concentrations of
EGF and HGF significantly increased growth
(p[0.0001) in the SKOV-3 cell aggregates
(Fig. 2b).
Canertinib and PHA665752 Alone Inhibit
the Growth of Clusters and Aggregates
We next investigated whether growth of cell
clusters and aggregates could be inhibited by the
Fig. 2 Combined growth factors induce cell growth and
canertinib inhibits cell growth of ovarian cancer cells.
Growth stimulation of OVCAR-5 (a), SKOV-3 (b) cells
incubated with 0.2 and 20 ng/ml epidermal growth factor,
EGF, or hepatocyte growth factor, HGF. Canertinib
inhibited cell growth of OVCAR-5 in a dose-dependent
manner in the presence of 0.2 ng/ml (c) and 20 ng/ml
(d) combined growth factors. Cell growth of SKOV-3
aggregates was markedly reduced by canertinib in the
presence of combined growth factors (e, f). All experiments
were independently performed at least three times with
triplicates. Data analyzed logarithmically using one-way
ANOVA. Data considered statistically signiﬁcant are
indicated as p\0.05 (*), p\0.01 (**), p\0.001 (***),
and p\0.0001 (****) when compared to the control or the
other doses
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EGFR/Her-2 inhibitor, canertinib. In their in vivo
microenvironment, floating ovarian cancer cells
are exposed to a mixture of growth factors (GF).
Therefore, we stimulated the cells with the
mixture of EGF and HGF. Canertinib inhibited
the growth activity in OVCAR-5 cell clusters, in a
concentration-dependent manner, in the
presence of low and high concentrations of
combined growth factors (p[0.0001) (Fig. 2c,
d). The inhibitor was very potent against SKOV-3
cell aggregates (p[0.0001) (Fig. 2e, f).
Interestingly, the inhibition of canertinib was
growth factor independent.
Wethenexamined theeffectof PHA665752on
growth. PHA665752 inhibited growth of
OVCAR-5 clusters in a concentration-dependent
manner (p[0.0001) (Fig. 3a, b). Its effect on
SKOV-3 aggregates was less pronounced, but
there still was a decrease in growth (p[0.05)
(Fig. 3c, d). Interestingly, growth inhibition by
PHA665752 in the presence of low and high
concentrationmixtures of growth factors was not
statistically different (data not shown).
Effect of a Combination of Both
Canertinib and PHA665752
We investigated the effects of a combination of
canertinib and PHA665752 at respective
concentrations of 3 lM and 1 lM, which were
the lowest effective doses from the single drug
treatment experiments. The combination of
Fig. 3 Inhibition of c-Met inhibitor, PHA665752 on cell
growth of ovarian cancer cells. PHA665752 inhibited cell
growth of OVCAR-5 clusters in a dose-dependent manner
in the presence of 0.2 ng/ml (a) and 20 ng/ml
(b) combined growth factors. Cell growth of SKOV-3
aggregates was marginally reduced by PHA665752 in the
presence of combined growth factors (c, d). All
experiments were independently performed at least three
times with triplicates. Data analyzed logarithmically using
one-way ANOVA. Data considered statistically signiﬁcant
are indicated as p\0.05 (*), p\0.01 (**), p\0.001 (***),
and p\0.0001 (****) when compared to the control or the
other doses
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these concentrations reduced total expression of
the cell proliferative protein marker, PCNA in
OVCAR-5 (Fig. 4a) and SKOV-3 (Fig. 4b) cells.
Growth was more reduced with the inhibitor
combination, than with the respective single
inhibitor alone, in both OVCAR-5 clusters
(Fig. 4c) and SKOV-3 aggregates (Fig. 4d)
(p[0.0001) in the presence of 0.2 ng/ml GF.
Similar patterns of inhibition were obtained with
20 ng/ml GF for OVCAR-5 and SKOV-3 (Fig. 5).
Canertinib and PHA665752 Reduce
Expression of EGFR, Her-2 c-Met,
and Their Downstream Signaling
Molecules in OVCAR-5 Cell Clusters
Both single and combined applications of the
inhibitors significantly reduced p-EGFR (Fig. 6a,
b) in OVCAR-5 cell clusters in the presence of
0.2 ng/ml GF. However, the total expression of
EGFRwas only reduced in canertinib-treated cells
(Fig. 6c). Both c-Met and phosphorylated-c-Met
proteins were significantly reduced with a single
treatment of PHA665752, and this was further
decreasedwiththecombination (Fig. 6a,d, e).The
combination of inhibitors reduced the total
expression of Akt (Fig. 6g) and there was a
tendency for reduction of Akt phosphorylation
(Fig. 6f). The phosphorylation of Erk was reduced
in a single treatment alone, but there was greater
reduction of p-Erk in the combined inhibitors
(Fig. 6h). The total expression of Erk (Fig. 6i) was
unchanged. Expression of Her-2 was
undetectable in OVCAR-5 cell clusters. With
20 ng/ml combined growth factors, an overall
reduction of total expression and
phosphorylation of EGFR, and c-Met was
observed with the inhibitor combination
(Fig. 7). Reductions in p-EGFR, EGFR, p-Met,
Met, p-Akt, Akt and p-Erk were observed.
Canertinib and PHA665752 Reduce
the Expression of EGFR, Her-2 c-MET,
and Their Downstream Signaling
Molecules in SKOV-3 Cellular Aggregates
Single treatment of SKOV-3 cell aggregates with
canertinib reduced the amount of p-EGFR
Fig. 4 The effect of the combination of canertinib and
PHA665752 on the growth of ovarian cancer cells. The
expression of proliferative cell nuclear antigen (PCNA)
and a reference protein (GAPDH) in ovarian cancer cells
treated with single inhibitors and combination in
OVCAR-5 (a) and SKOV-3 (b). Cell numbers of
OVCAR-5 cells (c) and SKOV-3 (d) were reduced with
single and combination of both inhibitors compared to
untreated cells in presence of 0.2 ng/ml combined growth
factors. All experiments were independently performed at
least three times with triplicates. Data analyzed using
one-way ANOVA. Data considered statistically signiﬁcant
are indicated as p\0.05 (*), p\0.01 (**), p\0.001 (***),
and p\0.0001 (****) when compared to the control or the
other doses
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(Fig. 8a), while the application of PHA665752
alone did not reduce p-EGFR. The combination
treatment gave a similar result to canertinib
alone (Fig. 8b). The total expression of EGFR
itself was also reduced with canertinib, and with
the combination treatment (Fig. 8c).
Phosphorylation and total expression of Her-2
was significantly reduced in both the canertinib
and the combination treatment (Fig. 8d, e).
Canertinib alone and the combination
significantly reduced the phosphorylation of
c-Met (Fig. 8f). The single inhibitor treatment
reduced the total expression of c-Met, but a
greater reduction was observed in the
combination (Fig. 8g). The reduction of p-Akt,
and p-Erk were also notable in the combination
treatment. The total expression of Erk was
slightly reduced in the canertinib and
combination treatment. Similar results were
obtained when cells were activated with 20 ng/
ml combined GF (Fig. 9).
DISCUSSION
A subset of advanced ovarian cancer cells have
previously been shown to express high levels
of receptor tyrosine kinases that are associated
with rapid growth and proliferation. EGFR
and Her-2 were upregulated in 53% and 25%
of patients with advanced ovarian cancers,
respectively, and these were thought to be
associated with resistance to chemotherapy
and a poor prognosis [8]. Likewise, Swada
et al. have shown that c-Met expression
increased in 11% of ovarian cancer patients
[17], and Davies et al. report that 96% of
ovarian cancer patients have positive
expression of c-Met in their cancerous tissue
[10]. Thus, it is very plausible that cells may
have an ability to activate multiple receptors,
and this rationale has been described by other
studies [2, 17, 18]. Co-activation of multiple
receptor tyrosine kinases may reduce the
Fig. 5 The effect of the combination of canertinib and
PHA665752 on the growth of ovarian cancer cell in the
presence of 20 ng/ml combined growth factors. Expression
of proliferative cell nuclear antigen (PCNA) and a
reference protein (GAPDH) in ovarian cancer cell clusters
treated with single inhibitors and combination in
OVCAR-5 (a) and SKOV-3 (b). Cell numbers of
OVCAR-5 cells (c) and SKOV-3 (d) were reduced with
single and combination of both inhibitors compared to
untreated cells in presence of 20 ng/ml combined growth
factors. All experiments were independently performed at
least three times with triplicates. Data analyzed using
one-way ANOVA. Data considered statistically signiﬁcant
are indicated as p\0.05 (*), p\0.01 (**), p\0.001 (***),
and p\0.0001 (****) when compared to the control or the
other doses
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clinical efficacy of any single drug that targets
one of the receptors [19, 20]. Therefore,
targeting multiple receptor tyrosine kinases
may improve clinical efficacy. Our study
attempts to employ such a combined
approach by targeting the concurrent
activation of EGFR, Her-2 and c-Met. Our
study has used a 3D cell culture, in which
the generation of cell clusters and aggregates
replicates the phenotypic and cellular
heterogeneity of floating ovarian malignant
cells that are present in ascitic fluid. As such
these experiments may be a better
representation of the possible response to the
combination of drugs in vivo [21, 22].
Consistent with previous reports, we found
that the OVCAR-5 cells formed small clusters
while the SKOV-3 cells formed aggregates
[23, 24]. We also show that OVCAR-5 cell
clusters express high levels of EGFR and c-Met,
but low levels of Her-2 and that the SKOV-3
aggregates express high levels of all three
receptors. These observations are consistent
with a previous study [25]. In previous studies,
a variety of EGF and HGF concentrations have
been used ranging from 10 to 200 ng/ml
[26, 27]. However, these concentrations are
not physiologically relevant in women with
advanced ovarian cancer [28]. We show that a
concentration of 0.2 ng/ml, which is a more
Fig. 6 Inhibition of selective protein molecules in the
presence of canertinib and PHA665752 in OVCAR-5 cell
clusters with 0.2 ng/ml combined growth factors. Total
protein expression and phosphorylation of EGFR, Her-2,
c-Met, Akt and Erk in single and combination of
inhibitors. All experiments were independently performed
at least three times with triplicates. Data analyzed
logarithmically using one-way ANOVA. Data considered
statistically signiﬁcant are indicated as p\0.05 (*),
p\0.01 (**), p\0.001 (***), and p\0.0001 (****) when
compared to the control or other doses
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physiologically relevant level, elicits no
significant change in the growth of OVCAR-5
line, compared to a concentration of 20 ng/ml.
However, the growth of SKOV-3 cell line was
growth factor dependent. It is unclear therefore
to what extent EGF and HGF determine ovarian
cell growth in physiological conditions.
We have assessed the effect of canertinib, an
irreversible dual inhibitor for EGFR family of
receptor tyrosine kinases, and PHA665752, a
reversible, specific inhibitor for c-MET protein,
on both cell lines in the presence of EGF and
HGF which are the respective ligands for the
receptors [29]. In our study, the selective
concentrations of single drug treatments were
chosen on the basis of concentrations in a
mouse model previously described [30].
Canertinib binds irreversibly to the ATP pocket
of the intracellular domain of ErbB family
receptor tyrosine kinases, forming a covalent
bond that irreversibly blocks EGFR, Her-2 and
Her-3 signal transduction. Reversible small
molecule inhibitors of EGFR such as Gefitinib
(ZD1839, Iressa) and Erlotinib (OSI-774,
Tarceva) have been approved by the FDA for
treatment of NSCLC [31]. The anti-growth
Fig. 7 Inhibition of selective protein molecules in the
presence of canertinib and PHA665752 in OVCAR-5 cell
clusters with 20 ng/ml combined growth factors. Total
protein expression and phosphorylation of EGFR, Her-2,
c-Met, Akt and Erk in single and combination of
inhibitors. All experiments were independently performed
at least three times with triplicates. Data analyzed
logarithmically using one-way ANOVA. Data considered
statistically signiﬁcant are indicated as p\0.05 (*),
p\0.01 (**), p\0.001 (***), and p\0.0001 (****) when
compared to the control or the other doses
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properties of these drugs have been explored in
other EGFR-positive malignancies, and
unfortunately the majority of these trials have
failed to exhibit prolonged clinical effects
[32, 33]. The difference between canertinib,
and gefitinib and erlotinib [33], is that
canertinib irreversibly binds to the active site
of ATP, completely blocking the ATP-binding
process and thereby decreasing the activity of
EGFR and Her-2 permanently. Therefore, there
is a good rationale for utilizing an irreversible
inhibitor, in order to prolong the suppression of
EGFR family activity and their downstream
molecules [34].
We show that canertinib inhibits growth of
SKOV-3 cell aggregates in a dose-dependent
fashion. This effect may be due to the
abundant expression of EGFR and Her-2. In
contrast, OVCAR-5 cell clusters exhibited less
sensitivity to canertinib, possibly because they
Fig. 8 Inhibition of selective protein molecules in the
presence of canertinib and PHA665752 in SKOV-3 cell
clusters with 0.2 ng/ml combined growth factors. Total
protein expression and phosphorylation of EGFR, Her-2,
c-Met, Akt and Erk in single and combination of
inhibitors (a). All experiments were independently
performed at least three times with triplicates. Data
analyzed logarithmically using one-way ANOVA. Data
considered statistically signiﬁcant are indicated as p\0.05
(*), p\0.01 (**), p\0.001 (***), and p\0.0001 (****)
when compared to the control or the other doses
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might have other downstream mutations that
facilitate cell survival [35]. Irwin, et al. showed
that canertinib at 0.1 and 5 lM inhibit the
proliferative capacity of acute lymphoblastic
leukemia cells [36]. Canertinib used as a single
agent showed clinical responsiveness in Her-2
positive tumors of breast cancer patients [37].
In our study, we also demonstrate that c-Met
inhibitor PHA665752, when used as a single
agent, inhibits SKOV-3 and OVCAR-5 growth in
a dose-dependent manner. However, SKOV-3
cell aggregates seem to be less responsive to the
c-Met inhibitor, compared to OVCAR-5 clusters.
One possible explanation is that SKOV-3 cells
have a high level of Her-2 and that the SKOV-3
cells may be able to resist the inhibitory action
of the c-Met inhibitor. As a single agent,
PHA665752 has been shown to induce
apoptosis, cease cell proliferation and spread
in lung adenocarcinoma cells with k-Ras gene
mutations [38]. Ma et al. demonstrated that
PHA665752 inhibited the growth of
Fig. 9 Inhibition of selective protein molecules in the
presence of canertinib and PHA665752 in SKOV-3 cell
aggregates with 20 ng/ml combined growth factors. Total
protein expression and phosphorylation of EGFR, Her-2,
c-Met, Akt and Erk in single and combination of
inhibitors. All experiments were independently performed
at least three times with triplicates. Data analyzed
logarithmically using one-way ANOVA. Data considered
statistically signiﬁcant are indicated as p\0.05 (*),
p\0.01 (**), p\0.001 (***), and p\0.0001 (****) when
compared to the control or the other doses
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BaF3.TPR-Met cells in a dose-dependent manner
[39] and Christensen et al. showed that
PHA665752 at a concentration range of
0.1–5.0 lM inhibited growth of gastric,
pancreatic, and lung carcinoma cell lines
[14, 40]. Other studies have shown NSCLC and
gastric cancer cells are sensitive to
concentrations of PHA665752 between 0.01
and 10 lM [9].
In our study, we demonstrate that the
combined inhibitors (using the lowest effective
single treatment concentration of each
inhibitor) elicit a greater reduction of cell
growth than a single agent alone. This finding
may suggest that the combination of EGFR/
Her-2 and c-Met inhibitors is sufficient to block
multiple cellular pathways and that can
compromise the growth and survival of cancer
cells. The rationale of combined targeting with
multiple drugs has been highlighted in recent
years. Engelman et al. demonstrated that a
combination of gefitinib and PHA665752
reduced cell proliferation more than a single
treatment alone, in NSCLC and gastric cancer
cell lines [9], while Crosswell et al. indicated
that combining PHA665752 with rosiglitazone
strongly inhibited cell growth of a
neuroblastoma cell line [41]. In addition, Tang
et al. demonstrated that the inhibition of both
EGFR and c-Met receptors strongly
compromised the growth activity of
EGFR-mutation mediated erlotinib-resistant
lung cancer cells [42].
In clinical trials, the combination of
cytotoxic agents with small molecule receptor
tyrosine kinase inhibitors or monoclonal
antibodies has been also investigated in
ovarian and other cancers. The combination of
cetuximab, a monoclonal antibody to EGFR,
and paclitaxel and carboplatin is adequately
tolerated as a primary therapy for ovarian
cancer but does not demonstrate the increase
of progression-free survival [43]. The
combination of lapatinib plus topotecan for
the treatment of platinum-resistant ovarian
cancer showed limited clinical benefit [44].
Chun et al. showed that a combination of
gemcitabine and gefitinib synergistically
reduced cell growth of head and neck cancer
cells in an in vitro and an in vivo animal model,
and the phosphorylation of EGFR and the
downstream molecule Erk was also down
regulated [45]. Furthermore, breast cancer
patients treated with the combination of
capecitabine with the Her-2 antibody,
trastuzumab, or with lapatinib showed clinical
activity, but increased side effects were noticed
[46, 47]. Certainly, the present study is limited
given the lack of any preclinical animal model
study. This would be essential to confirm the
efficacy of our combination inhibitors and to
identify potential adverse side effects.
CONCLUSION
Studying the SKOV-3 and OVCAR-5 ovarian
cancer cell lines in vitro, we demonstrate a
significant effect on growth of a combination of
two tyrosine kinase inhibitors that block three
receptor tyrosine kinases. Further work is
required to elaborate these effects in animal
and human studies. SKOV-3 and OVCAR-5 cell
lines do not entirely represent in vivo ovarian
cancer cells. Therefore, we need to know if these
effects are seen in other cell lines, including
primary ovarian cancer cells from patients, and
how the effects correlate with the receptor
status. The combination of receptor tyrosine
kinase inhibitors at effective concentrations
may, however, have the effect of increasing
toxicity. Animal studies are essential to assess
any adverse side effects prior to any clinical
trials.
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